This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Long-term Cardiovascular Risk in Cured Cushing's Patients

This study has been terminated.
(Decision made to close study early.)
Sponsor:
Information provided by (Responsible Party):
Anne Klibanski, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00881283
First received: April 13, 2009
Last updated: January 19, 2017
Last verified: April 2015
  Purpose
The purpose of this study is to determine whether subjects who have been affected by Cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.

Condition
Cushing's Disease

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Role of Adipokines in Long-term Cardiovascular Risk in Cured Cushing's Patients

Resource links provided by NLM:


Further study details as provided by Anne Klibanski, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • adipokine measurements [ Time Frame: baseline ]

Biospecimen Retention:   Samples With DNA
serum, urine

Enrollment: 1
Actual Study Start Date: September 8, 2008
Study Completion Date: March 30, 2010
Primary Completion Date: March 30, 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
cured Cushing's disease

  Eligibility

Ages Eligible for Study:   35 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cured Cushing's disease
Criteria

Inclusion Criteria:

  • patients who have been cured of Cushing's disease at least 5 years ago.

Exclusion Criteria:

  • patients who have been cured of Cushing's disease more than 15 years ago.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00881283

Locations
United States, Massachusetts
Neuroendocrine Clinical Center
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Anne Klibanski, MD Massachusetts General Hospital
  More Information

Responsible Party: Anne Klibanski, MD, PI, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00881283     History of Changes
Other Study ID Numbers: 2008-p-001379
Study First Received: April 13, 2009
Last Updated: January 19, 2017

Keywords provided by Anne Klibanski, MD, Massachusetts General Hospital:
Cushing's disease

Additional relevant MeSH terms:
Pituitary ACTH Hypersecretion
ACTH-Secreting Pituitary Adenoma
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on August 23, 2017